Rationale and design of a randomized, double‐blind, event‐driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial

Rationale and design of a randomized, double‐blind, event‐driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial

Bibliographic Details
Main Authors: Zannad, Faiez, Greenberg, Barry, Cleland, John G.F., Gheorghiade, Mihai, van Veldhuisen, Dirk J., Mehra, Mandeep R., Anker, Stefan D., Byra, William M., Fu, Min, Mills, Roger M.
Format: Online
Language:English
Published: John Wiley & Sons, Ltd 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029775/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029775/

Similar Items